NEJM This Week: DOACs in atrial fibrillation, orexin-2 agonists and gene therapy results
Start here
NEJM This Week, published on October 17, 2026, surveys new studies spanning anticoagulation, sleep medicine, cancer immunotherapy, gene therapy, genomics and public health. A Korean randomized trial found direct oral anticoagulants superior to no anticoagulation on a 24-month composite endpoint in atrial fibrillation patients with a single stroke risk factor, though the small sample may overstate the effect. Orexin-2 receptor agonists met their endpoints in two phase 3 trials for type 1 narcolepsy. Lentiviral gene therapy for Wiskott-Aldrich syndrome showed 96% overall survival at 5.7 years of follow-up. Additional findings across the surveyed fields are discussed in the accompanying expert commentary. Full trial details and longer-term data remain open questions for the individual studies.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comNEJM This Week covers DOACs in atrial fibrillation, orexin-2 agonist phase 3 trials and gene therapies
NEJM This Week surveys studies across anticoagulation, sleep medicine, cancer immunotherapy, gene therapy, genomics and public health. A Korean randomized trial found DOACs superior to no anticoagulation on a 24-month composite endpoint in atrial fibrillation patients with a single stroke risk factor, though the small sample may overstate the effect. Orexin-2 receptor agonists met endpoints in two phase 3 trials for type 1 narcolepsy, and lentiviral gene therapy for Wiskott-Aldrich syndrome showed 96% overall survival at 5.7 years of follow-up.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.